Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5

Mavrakis, Konstantinos J., McDonald, E. Robert, Schlabach, Michael R., Billy, Eric, Hoffman, Gregory R., deWeck, Antoine, Ruddy, David A., Venkatesan, Kavitha +36 more·2016·Science
DOI 10.1126/science.aad5944

Cited by (623)

Items 501–600 of 623

  1. Determination of Exercise Capacity Indices Using Acoustic Signal Analysis
    Qi Zhang · 2020 · TSpace (University of Toronto)
  2. Energy Metabolism and Epigenetics
    Scott J. Bultman · 2019 · Springer eBooks
  3. Faculty Opinions recommendation of PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
    Scott A. Ness · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  4. Análise da efetividade e toxicidades da quimioterapia adjuvante no adenocarcinoma de pâncreas: estudo de mundo real realizado em um hospital terciário do Sistema Único de Saúde
    Anny Alves Pereira Trevisan · 2022
  5. Decision letter: Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction
    2022 · eLife
  6. Author response: Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction
    Jacob M. Winter, Heidi L. Fresenius, Corey Nathaniel Cunningham, Peng Wei, Heather R. Keys, Jordan A. Berg, Alex J. Bott, Tarun Yadav, Jeremy A. Ryan, Deepika Sirohi et al. · 2022 · eLife
  7. Editor's evaluation: Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction
    Erica A. Golemis · 2022 · eLife
  8. Immunohistochemical Study of 5-Methylthioadenosine Phosphorylase (MTAP) and Epithelial Membrane Antigen (EMA) in Differentiating Epithelioid Pleural Mesothelioma from Reactive Mesothelial Hyperplasia
    Nehal Hussien, Mohamed Moustafa Shareef, Yomna Zamzam, Asmaa Eid · 2023 · International Journal of Cancer and Biomedical Research
  9. Data from MTAP Deficiency–Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer
    Qiangsheng Hu, Yi Qin, Shunrong Ji, Xiuhui Shi, Weixing Dai, Guixiong Fan, Shuo Li, Wenyan Xu, Wensheng Liu, Mengqi Liu et al. · 2023
  10. Data from Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA
    Carolin Dorothea Strobl, Stefanie Schaffer, Tabea Haug, Simon Völkl, Katrin Peter, Katrin Singer, Martin Böttcher, Dimitrios Mougiakakos, Andréas Mackensen, Michael Aigner · 2023
  11. Characterising Changes in Lipid Homeostasis as an Anti-Cancer Mechanism of Action of Methylthio-DADMe-Immucillin-A
    Timothy Salita · 2018
  12. Chromosome 9
    Thilaga Thirugnanam, Yamini Chandrapraksh, Sivasankari Ramadurai, Abhishek Mitra, Ravi Gor, Saurav Panicker, Satish Ramalingam · 2023 · BENTHAM SCIENCE PUBLISHERS eBooks
  13. Biology of cancer: current insights and perspectives
    Sushruta S. Hakkimane, Santosh Laxman Gaonkar · 2023 · Elsevier eBooks
  14. Loss of CYP2D6 sensitizes hepatocellular carcinomas and neuroblastomas to talazoparib
    Tobias Sjöblom, Xiaonan Zhang, Natallia Rameika, Lei Zhong, Verónica Rendo, Snehangshu Kundu, Sandro Nuciforo, Jordan Dupuis, Muhammad Azhar, Ioanna Tsiara et al. · 2023 · Research Square
  15. PRMT5 inhibitors for lower-risk myelodysplasia: Is there anywhere to move?
    Andrej Terzic, David J. Curtis · 2023 · Leukemia Research
  16. Klinische Genom- und Transkriptomsequenzierung
    Stefan Fröhling · 2023 · Forum
  17. RECENT ADVANCES IN TARGETING THE PRMT5/MTA COMPLEX
    Christopher R. Smith, Matthew A. Marx · 2023 · Medicinal chemistry reviews
  18. Targeting MTAP creates a therapeutic vulnerability to PARP inhibition in brain metastatic TNBC by disrupting MAT2A mediated methionine metabolism
    Zhenkun Lou, Xiangyu Zeng, Fei Zhao, Lingxin Zhang, Richard M. Weinshilboum, Kaixiong Tao · 2023 · Research Square
  19. Drug Discovery for Chromatin Readers, Writers, Erasers, Remodelers and Epitranscriptomic Targets
    2024 · Royal Society of Chemistry eBooks
  20. Case Studies
    2024 · Royal Society of Chemistry eBooks
  21. Emerging Technologies for Epigenetic Drug Discovery
    2024 · Royal Society of Chemistry eBooks
  22. Hábitos de vida e suas relações com grandes deleções e amplificações na determinação do câncer de pele: um estudo piloto
    Christopher William Lee, Carlos Henrique Schneider, Maria Leandra Terêncio, Patrícia Oliveira de Paula, Luís Fernando Boff Zarpelon, Maria Cláudia Gross · 2024 · Caderno Pedagógico
  23. From Normalcy to Neoplasia: Mutational Events During Bladder Tumor Evolution
    Khyati A. Meghani, Joshua J. Meeks · 2024 · Springer eBooks
  24. PRMT5 Inhibition Enhances Therapeutic Efficacy of Cisplatin via Mediating miR‐29b‐3p‐Mcl‐1 Expression in Lung Adenocarcinoma
    Haichao Li, Jiangjiang Fan, Weiwei Shen, Yong Zhang, Ximing Zhu, Pei Li, Zhongping Gu, Pengyu Jing · 2025 · Cell Biology International
  25. Fabp4 is essential for the maintenance of leukemia stem cells while sparing hematopoietic stem cells
    Xing Cheng, Huifang Zhang, Mengqiu Zheng, Qian Lu, Yujia Tao, Shina Xu, Yang Xiao, Long Liang, Shuqian Xu, Shuqian Xu et al. · 2025 · Leukemia
  26. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
    Youyou Zhang, Mu Xu, Jiao Yuan, Zhongyi Hu, Junjie Jiang, Yanrong Sun, Jie Sheng Huang, Yuxin Wang, Bingwei Wang, Jianfeng Shen et al. · 2025 · eLife
  27. Arginine methylation regulates Ewing sarcoma cell viability in a EWSR1::FLI1 dependent manner and provides a therapeutic opportunity
    Ciara M. Ward, Charles Brockwell, Gavin S. McNee, Emily Orton, Emily N. P. Prowse, Susanne A. Gatz, Clare C. Davies · 2025 · Frontiers in Oncology
  28. Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
    Youyou Zhang, Mu Xu, Jiao Yuan, Zhongyi Hu, Junjie Jiang, Yanrong Sun, Jie Sheng Huang, Yuxin Wang, Bingwei Wang, Jianfeng Shen et al. · 2025 · eLife
  29. Thermodynamics of transition state analogs
    Vern L. Schramm, Ashleigh S. Paparella · 2025 · Elsevier eBooks
  30. Clinical Impact of MTAP Rearrangement in Pediatric Acute Lymphoblastic Leukemia: Insights From Whole Transcriptome Analysis
    Sidong Zhang, Zhengyu Wu, Yufeng Liu, Bai Li, Yadong Song · 2025 · Pediatric Blood & Cancer
  31. The cytosolic PRMT5-CDK4 complex impairs cell cycle kinase signaling
    Sarah Masser, Tanja Lotteritsch, Anton Emil Ludwig, Bettina Halwachs, Elisabeth Annerer, Marion Mußbacher, Ulrich Stelzl · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  32. Additional file 1 of SNHG3 could promote prostate cancer progression through reducing methionine dependence of PCa cells
    Wang, Xiaotian, Song, Yongsheng, Yaxing Shi, Yang, Da, Li, Jiaxing, Yin, Bo · 2022 · Figshare
  33. Additional file 1 of Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
    Dominici, Claudia, Nicolas Sgarioto, Zhenbao Yu, Laura Sesma-Sanz, Jean‐Yves Masson, Stéphane Richard, Noël J.‐M. Raynal · 2021 · Figshare
  34. Additional file 1 of Mitoferrin2 is a synthetic lethal target for chromosome 8p deleted cancers
    Krieg, Stephan, Thomas Rohde, Rausch, Tobias, Luise Butthof, Lena Wendler-Link, Eckert, Christoph, Kai Breuhahn, Bruno Galy, Jan O. Korbel, Billmann, Maximilian et al. · 2024 · Figshare
  35. Additional file 2 of Mitoferrin2 is a synthetic lethal target for chromosome 8p deleted cancers
    Krieg, Stephan, Thomas Rohde, Rausch, Tobias, Luise Butthof, Lena Wendler-Link, Eckert, Christoph, Kai Breuhahn, Bruno Galy, Jan O. Korbel, Billmann, Maximilian et al. · 2024 · Figshare
  36. Discovery of Bis-Acyl Hydrazides as Potent and Bioavailable MTA-Cooperative PRMT5 Inhibitors: A Case Study of Leveraging the Deuterium Kinetic Isotope Effect
    Laurent Debien, Megan K. Armstrong, Joshua D. Farr, Ryan Ferrao, Pancham Lal Gupta, Congrong Niu, Andrew J. Anderson, Phillip Benner, Ashleigh N. Bristol, Elbert Chin et al. · 2025 · Journal of Medicinal Chemistry
  37. Targeting PRMT5 in Adult T-Cell Leukemia/Lymphoma: Opportunities and Challenges
    Kyle Ernzen, Amanda R. Panfil · 2026 · Viruses
  38. Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer
    Takashi Sakai, Zofia Piotrowska, Charlotte I. Wang, Beow Yong Yeap, Rebecca Suk Heist, Jessica J. Lin, Lauren Highfield, Jennifer L. Petersen, Mandeep K. Banwait, Joyce H. Liang et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  39. PRMT5 inhibition induces a histone methylation switch that drives chromatin plasticity, drug resistance, and metastatic progression
    Colin E Fowler, Natalie A. O’Hearn, Nicole Henning, Anthony J. Griffen, Ziyang Ye, Nicolas Mathey‐Andrews, Griffin Salus, Renin Hazan, Tyler Jacks, Aurora Burds et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  40. Inhibition of PRMT5-dependent YAP methylation attenuates tumorigenicity and radioresistance in glioblastoma
    Mei Luo, Shiyu Wu, Chenxin Huang, Ziyuan Zheng, Qiaoxi Xia, Yonghua Li, Xiao Zhou, Shihong Hong, Ronghui Zhong, Weijie Li et al. · 2026 · Cancer Letters
  41. Targeting one-carbon metabolic vulnerabilities of metastasis with therapeutic potential
    Yanlin Yu, W C Chen, Glenn T Merlino · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  42. Coupled-enzyme assay for MTAP activity in biological samples
    Nord Gilaj, Andrew G. Wagner, Terence Li, Dior Dedushi, Roozbeh Eskandari, Chaoyuan Kuang, Vern L. Schramm · 2026 · Analytical Biochemistry
  43. PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath Tumors
    Dingxun Wang, Melissa L. Fishel, Azadeh Samiei, Silpa Gampala, Chang‐Deng Hu, Shaoxiong Chen, Guangjun Zhang · 2026 · SSRN Electronic Journal
  44. Cancer biology and the principles of targeted cancer drug discovery
    A. Davies, G. Jones, S. Krishnan, M. Krishnamoorthy, M. Maruggi, M. Kaneda, K. Marjon · 2026 · Elsevier eBooks
  45. Systemic Therapy for Advanced Pancreatic Cancer in 2025: Current Standard‐of‐Care and Emerging Therapeutic Strategies
    Gin Wai Kwok, Jenny Lo, Tiffany H.W. Fung · 2026 · Journal of Gastroenterology and Hepatology
  46. Reprogramming of amino acid metabolism in cholangiocarcinoma: A potential target for metabolic-targeted therapy
    Kullanat Khawkhiaw, Worachart Lert-itthiporn, Naisana Seyedasli, Ching‐Feng Chiu, Charupong Saengboonmee · 2026 · World Journal of Gastroenterology
  47. Identification of a lineage-agnostic splicing signature caused by PRMT5 inhibition
    Matthew R. Tonini, Samuel R. Meier, Shangtao Liu, Kevin M. Cottrell, John P. Maxwell, Jannik N. Andersen, Alan Huang, Luisa Cimmino, Kimberly J. Briggs · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  48. Mesothelioma: a systemic therapy clinical trials snapshot
    Maurice R. Dungey, Rushad Malhotra Mukhtyar, Sean Dulloo, Dean Anthony Fennell · 2026 · Trends in cancer
  49. Analysis of protein arginine methyltransferase 5 as a therapeutic target in triple-negative breast cancers
    Mathilde Vinet · 2019
  50. Analysis of the Protein Arginine Methyltransferases 1 (PRMT1) and 4 (PRMT4) in Triple-Negative Breast Cancer
    Samyuktha Suresh · 2021
  51. Meeting report on FASEB protein arginine methylation: mechanism to therapeutics
    David Shechter, Rong Huang, Pooja Anil Shah, Thierry Dubois, Xiao-Meng Li, Andrey A. Parkhitko, Mark T. Bedford, Shihuan Kuang, Taiping Chen, Yanzhong Yang et al. · 2026 · Journal of Biological Chemistry
  52. Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies
    Riccardo Bevilacqua, Paola Gasperini, Thomas Cantore, Catarina Macedo‐Silva, Michael Pancher, Martina Radić, Haiyan Yue, Orsetta Quaini, Tarcisio Fedrizzi, Pamela Gatto et al. · 2026 · npj Precision Oncology
  53. Identification of Combinatorial Targets for Anticancer Drug Discovery
    Min Huang, Meiyu Geng · 2026 · 中国科学基金
  54. Mechanistic Investigation of a Domino N–H and C–H Borylation in the Manufacture of AMG 193
    Conner V. Wilson, Maria Victoria Silva Elipe, Sharon E. Michalak, Ted C. Judd, Neil F. Langille, James I. Murray · 2026 · Organic Process Research & Development
  55. Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer
    Rongjie Fu, Yalong Wang, Ishita Rehman, Ella Bedford, Sana Sharif, Nghi D. Nguyen, Reid Trenton Powell, Andrew Adams, W LIU, Shuyue Wang et al. · 2026 · Biomolecules
  56. Design and Discovery of Pyridazinone-Based MAT2A Inhibitors Targeting MTAP-Deficient Cancers
    Yu Zhang, Pengfei Wang, Zhicheng Xie, Yilun Huang, Yaqi Ding, Jia Liu, Yi Chen, Youhong Hu · 2026 · Journal of Medicinal Chemistry
  57. Targeting purinergic signaling and MTAP-associated metabolism in cancer: A functional immunometabolic convergence framework
    Vandriel P. da Rosa, Michelli Fontana, Carine Raquel Richter Schmitz, Maike V. Buzatto, Iuri Raiel Giacomelli, Walter Antônio Roman, Detlev Boison, Margarete Dulce Bagatini, Sarah Franco Vieira de Oliveira Maciel · 2026 · Biochemical Pharmacology
  58. MTAP loss in gallbladder carcinoma: frequency, heterogeneity and expression in precursor lesions
    Valentina Angerilli, Jessica Gasparello, Monia Niero, Giacomo Zanus, Matteo Fassan · 2026 · Journal of Clinical Pathology
  59. Sequential multimodal management for recurrent pulmonary NUT carcinoma: a case report
    Jincheng Su, Zirong Mi, Haizhou Yue, Dongliang Bian, Peng Zhang · 2026 · Frontiers in Oncology
  60. Structure-based discovery of a highly potent, selective, and brain-penetrant MTA-cooperative PRMT5 synthetic lethal inhibitor for the treatment of glioblastoma
    Bang Li, Xingcan Wang, Jinqi Yu, Qinfa Xie, Qiongyu Shi, Shuxian Li, Meiyu Geng, Xun Huang, Yuanxiang Wang, Hong Yang · 2026 · European Journal of Medicinal Chemistry
  61. Molecular Biomarkers in Urothelial Carcinoma: Current Insights and Future Directions
    Emanuele Crupi, Daniele Raggi, Arlene Odelia Siefker-Radtke, Jianjun Gao · 2026 · Cancer drug discovery and develogment/Cancer drug discovery and development
  62. Peri-Implant Gingival Undifferentiated SWI/SNF Complex-Deficient Tumor with Molecularly Confirmed Biallelic SMARCA4 Inactivation: Diagnostic Pitfalls and Genomic Characterization
    Haim Ohayon, Ahmad Hija, Amir Bilder, Tal Capucha, Sharon Jill Akrish, Amir Wolff, Omri Emodi · 2026 · Diagnostics
  63. MTAP deficiency is a novel biomarker in neuroendocrine neoplasms of the lung
    Magdalena M. Brune, Luca Roma, Nikolaus Deigendesch, Felix Meissner, Sarp Uzun, Juergen Hench, Obinna Chijioke, Ivana Bratić Hench, Jumpei Kashima, Petra Hirschmann et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  64. Quantitative Global Proteomics of Formalin-Fixed Paraffin-Embedded Tumors Identifies Dimethylated G3BP1 at Arginine 460 as a Robust Pharmacodynamic Biomarker of Methylthioadenosine Phosphorylase-Selective Protein Arginine Methyltransferase 5 Inhibition
    Anqi Tu, Elizabeth J. Wiseman, Steve M. M. Sweet, Jelena Urosevic, Joanna I. Loizou, Alan Barnicle, Christopher Richardson, Sudhanshu Abhishek, David C. Chain, Yeoun Jin Kim et al. · 2026 · Journal of Proteome Research
  65. A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
    Filemon S. Dela Cruz, Daoqi You, Tamar Y. Feinberg, Samantha Brosius, Xinyi Wang, Joseph G.W. McCarter, Dylan Domenico, Jesús Gutiérrez‐Abril, Juan Arango Ossa, Gunes Gundem et al. · 2026 · Cancer Research
  66. Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications
    Peiwen Yang, Xin-Yi Xu, Ju-Ying Jiao, Fang Wang, Z Chen · 2026 · Experimental Hematology and Oncology
  67. MTAP deficiency enhances collective metastasis in non-small cell lung cancer via WNT3A methylation
    Yang Chen, Hongfei Yan, Ye Zhang, Qikun Lv, Ran Ren, Jiajun Wang, Lirong Yan, Yongpeng He, Kezuo Hou, Yunpeng Liu et al. · 2026 · Oncogene
  68. Targeting PRMTs with small-molecule inhibitors: a comprehensive review
    Monica Viviano, Alessandra Cipriano, Benito D'Ascoli, Ciro Milite, Sabrina Castellano, Gianluca Sbardella · 2026 · RSC Medicinal Chemistry
  69. A highly selective 1,2-dihydroquinoxaline derivative as a potent PRMT5-MTA complex inhibitor
    Yiru Liu, Zhihao Jiao, Daoguang Zhang, Xiaoxi Xu, Ye Jia, Hongjun Wang, Guisen Zhao · 2026 · Bioorganic & Medicinal Chemistry
  70. Design, synthesis and evaluation of benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one derivatives as novel MTA cooperative PRMT5 inhibitors for the treatment of MTAP-deleted cancers
    Bing Liu, Shao-Yan Li, Hui Shi, Xian-Jing Hu, Xiao-Guang Pan, Jin-Shan Liu, Ze Zhuang, Ning Kang, Qian Wang, Ying-Jun Zhang et al. · 2026 · Bioorganic Chemistry
  71. Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling
    Jun Kim, Seounghun Kang · 2026 · Pharmaceutics
  72. Discovery of a Potent, Selective, and Orally Bioavailable Achiral MAT2A Inhibitor for Treating MTAP-Deficient Cancers
    Lijie Lin, Zhiyin Xie, Jiayue Liu, Zhehuan Fan, Zihan Shi, 孙要良, Kexin Lin, Rongrong Cui, Xinyu Jiang, Xiaomin Luo et al. · 2026 · Journal of Medicinal Chemistry
  73. Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
    Valentina Spielmann, Jonas Buchloh, Selen Selcen, Carolin Schneider, Shaishavi Jansari, Xin Fang, Ningjun Duan, Engin Demirdizen, Lukas Krauß, Jessica Eggert et al. · 2026 · Cancer Research Communications
  74. A case report of FUS::TFCP2 fusion sarcoma lacking myogenic and epithelial markers
    Renjie Wang, Qiying Zhu, Zhihong Jia, Yinghong Wu, Liying Feng · 2026 · Discover Medicine
  75. Arginine methylation as a regulatory ratchet in cancer: From substrate selection to malignant‐state stabilization
    So Hyun Kwon, Ji Min Lee · 2026 · Molecular Oncology
  76. Targeting metabolic reprogramming in cancer: Past, present, and future
    Niti Kumari, Surendra Kumar Shukla, Ravi Thakur · 2026 · Pharmacology & Therapeutics
  77. Genome-wide CRISPR screens map synthetic lethal interactions across recurrent cancer driver alterations
    Jessica Desjardins, Julian Bowlan, Cynthia Bernier, Srishti Jain, Théo Goullet de Rugy, David Gallo, Mark E. Orcholski, Nancy Laterreur, Abira Rajah, Joshua Miller et al. · 2026 · Cell Reports
  78. The Methionine-Mitochondria Axis in Cancer: Metabolic Cross-Talk and Therapeutic Vulnerabilities
    Md Salman Shakil, Matthew J. McBride · 2026 · Current Pharmacology Reports
  79. Catalytical nanogels reprogram immunosuppressive metabolic networks for activatable cancer photo-immunotherapy
    Mengting Yi, Mengyao Wu, Jianwei Zhang, Chang Xue, Congqiang Long, Lichang Zhang, Yilan Zhao, Fangxu Ning, Xuelei Hu, Chi Zhang · 2026 · Journal of Controlled Release
  80. Immunohistochemistry Resolves Indeterminate MTAP Deletion Calls From Exome Sequencing: A Pan-Cancer Concordance Study
    Marion Thibaudin, Julie Lecuelle, Anthony Bergeron, Valentin Derangere, Hugo Mananet, Léa Hampe, Susy Daumoine, Sandy Chevrier, Ana Costa, Natacha Moulharat et al. · 2026 · Modern Pathology
  81. Discovery of GTA182, a Novel CNS-Active Tricyclic Amide MTA-Cooperative PRMT5 Inhibitor for MTAP -Deleted Cancers
    Bing Yao, Weifeng Mao, 王明华, Junqing Zhang, Shanshan Xie, Kai Cheng, Xinbo Hu, Wei Liu, Xiangping Zhang, Zhu Zhengqing et al. · 2026 · Journal of Medicinal Chemistry
  82. Targeting protein arginine methyltransferases to enhance cancer immunotherapy
    Nivine Srour, Chunxiao Zhao, Stéphane Richard · 2026 · Cell chemical biology
  83. Protein arginine methylation rewires molecular interactions
    Joseph D. DeAngelo, Aliza M. Silverstein, David Shechter · 2026 · Cell chemical biology
  84. MTAP Loss and Pleural Mesothelioma (PM): Current Treatment Strategies and Emerging Therapeutic Approaches
    S. Cedrés, Laura Masfarré, Ilaria Priano, Augusto Valdivia, Pedro Rocha, Patricia Iranzo, Núria Pardo, Alex Martínez‐Martí, Aina Arbusà, Lucía Cané et al. · 2026 · Cancers
  85. Features of cancer cell metabolism linked to DNA repair mechanisms.
    R. Mikheeva, P. Leonov, M. Koryukov, Ekaterina Ruleva, Xue-Song Liu, A. Kechin · 2026 · DNA Repair
  86. Therapy-induced methionine competition in bladder cancer: MAT2A-SAM axis remodeling as a metabolic immune checkpoint
    Chengyuan Zhang, Zhe Zhang, 毕建斌 · 2026 · Frontiers in Immunology
  87. Targeting the MTAP–PRMT5 axis: from synthetic lethality to emerging therapeutic opportunities
    Vassilis Genoud, Maxime Borgeaud, Mihaela D. Aldea, Thibaud Koessler, Alfredo Addeo · 2026 · The Oncologist
  88. BindingDB Entry 50008922: Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.
    BindingDB · 2021 · UC San Diego
  89. BindingDB Entry 50016542: Paradoxical Increase of Permeability and Lipophilicity with the Increasing Topological Polar Surface Area within a Series of PRMT5 Inhibitors.
    BindingDB · 2023 · UC San Diego
  90. BindingDB Entry 50017717: Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads.
    BindingDB · 2023 · UC San Diego
  91. BindingDB Entry 50023151: Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion.
    BindingDB · 2026 · UC San Diego
  92. BindingDB Entry 50007537: Selective Inhibitors of Helicobacter pylori Methylthioadenosine Nucleosidase and Human Methylthioadenosine Phosphorylase.
    BindingDB · 2021 · UC San Diego
  93. BindingDB Entry 50020273: Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening.
    BindingDB · 2024 · UC San Diego
  94. BindingDB Entry 50021285: Development of a Series of Pyrrolopyridone MAT2A Inhibitors.
    BindingDB · 2025 · UC San Diego
  95. BindingDB Entry 50016955: Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors.
    BindingDB · 2023 · UC San Diego
  96. BindingDB Entry 50023341: From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo Efficacy.
    BindingDB · 2026 · UC San Diego
  97. BindingDB Entry 50018799: Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
    BindingDB · 2024 · UC San Diego
  98. BindingDB Entry 50002756: Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
    BindingDB · 2020 · UC San Diego
  99. BindingDB Entry 50023458: An update on small molecule compounds targeting synthetic lethality for cancer therapy.
    BindingDB · 2026 · UC San Diego
  100. BindingDB Entry 50021110: Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy.
    BindingDB · 2025 · UC San Diego